ReviewOncotarget2017
SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Beyond perfusion: a review of peptide radiopharmaceuticals for cardiovascular imaging.Npj imaging · 2025Review
- Emerging Molecular PET Imaging for Cell Death in Neurodegenerative Diseases.Journal of medicinal chemistry · 2025Review
- UsingQuantitative imaging in medicine and surgery · 2025Article
- The therapeutic effect of a novel GAPDH inhibitor in mouse model of breast cancer and efficacy monitoring by molecular imaging.Cancer cell international · 2024Article
- Tales from the future-nuclear cardio-oncology, from prediction to diagnosis and monitoring.European heart journal. Cardiovascular Imaging · 2023Review
- Emerging Nuclear Medicine Imaging of Atherosclerotic Plaque Formation.Journal of imaging · 2022Review
- Development of Duramycin-Based Molecular Probes for Cell Death Imaging.Molecular imaging and biology · 2022Review
- Radionuclide imaging of apoptosis for clinical application.European journal of nuclear medicine and molecular imaging · 2022Review
- Low-Parameter Small Convolutional Neural Network Applied to Functional Medical Imaging of Tc-99m Trodat-1 Brain Single-Photon Emission Computed Tomography for Parkinson's Disease.Journal of personalized medicine · 2021Article
- Article
- Article
- Metabolic Imaging in Cardio-oncology.Journal of cardiovascular translational research · 2020Review
- Rational design of caspase-responsive smart molecular probe for positron emission tomography imaging of drug-induced apoptosis.Theranostics · 2019Article
- Investigation of cis-4-[Molecular imaging and biology · 2018Article
- New methods to image unstable atherosclerotic plaques.Atherosclerosis · 2018Review
- Recent Advances in Zirconium-89 Chelator Development.Molecules (Basel, Switzerland) · 2018Review
- Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.Contrast media & molecular imaging · 2018Article
- Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.European journal of nuclear medicine and molecular imaging · 2017Review
- Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies.NPJ Regenerative medicine · 2017Review
- Recent Progress in PET and SPECT Myocardial Perfusion Imaging: From Radiopharmaceuticals to Imaging Innovations.Iranian journal of pharmaceutical research : IJPRReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing to the central role of apoptosis in many human diseases and the wide-spread application of apoptosis-based therapeutics, molecular imaging of apoptosis in clinical practice is of great interest for clinicians, and holds great promises. Based on the well-defined biochemical changes for apoptosis, a rich assortment of probes and approaches have been developed for molecular imaging of apoptosis with various imaging modalities. Among these imaging techniques, nuclear imaging (including single photon emission computed tomography and positron emission tomography) remains the premier clinical method owing to their high specificity and sensitivity. Therefore, the corresponding radiopharmaceuticals have been a major focus, and some of them like 99mTc-Annexin V, 18F-ML-10, 18F-CP18, and 18F-ICMT-11 are currently under clinical investigations in Phase I/II or Phase II/III clinical trials on a wide scope of diseases. In this review, we summarize these radiopharmaceuticals that have been widely used in clinical trials and elaborate them in terms of radiosynthesis, pharmacokinetics and dosimetry, and their applications in different clinical stages. We also explore the unique features required to qualify a desirable radiopharmaceutical for imaging apoptosis in clinical practice. Particularly, a perspective of the impact of these clinical efforts, namely, apoptosis imaging as predictive and prognostic markers, early-response indicators and surrogate endpoints, is also the highlight of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.